The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Addressing disparities in lymphoma treatment
Francine Foss, MD, Yale University School of Medicine, New Haven, CT, talks on potential disparities in lymphoma treatment and outcomes, especially in African-American patients with cutaneous T-cell lymphoma (CTCL), who may be perceived to have inferior outcomes. An analysis of patients across various centers will elucidate any potential associations between certain patient populations and treatment outcomes. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
